Get started
Author

Karen Kaucic

Observed name: K Kaucic
OpenAlex ID: A5025784315
Phase I and pharmacokinetic study of etaracizumab (Abegrin™), a humanized monoclonal antibody against αvβ3 integrin receptor, in patients with advanced solid tumors
2007 · Catherine Delbaldo, Eric Raymond, et al. · Investigational New Drugs · 101
EBV-Related Lymphoproliferative Disease Complicating Therapy with the Anti-CD2 Monoclonal Antibody, Siplizumab, in Patients with T-Cell Malignancies
2009 · Deirdre O'Mahony, John C. Morris, et al. · Clinical Cancer Research · 59
Reimagining patient-centric cancer clinical trials: a multi-stakeholder international coalition
2022 · Bob T. Li, Bobby Daly, et al. · Nature Medicine · 50
Modulation of Growth Factor Signaling by Gangliosides: Positive Or Negative?
2006 · Karen Kaucic, Yihui Liu, et al. · Methods in enzymology on CD-ROM/Methods in enzymology · 44
Low complex ganglioside expression characterizes human neuroblastoma cell lines
2005 · Simone Hettmer, Stephan Ladisch, et al. · Cancer Letters · 40
Induction of GM1a/GD1b synthase triggers complex ganglioside expression and alters neuroblastoma cell behavior; a new tumor cell model of ganglioside function
2011 · Lixian Dong, Yihui Liu, et al. · Glycoconjugate Journal · 34
Biological stratification of human neuroblastoma by complex "B" pathway ganglioside expression.
2003 · Simone Hettmer, Carolin Malott, et al. · PubMed · 31
Alterations in neuroblastoma ganglioside synthesis by induction of GD1b synthase by retinoic acid
2004 · S Hettmer, R McCarter, et al. · British Journal of Cancer · 29
Neuroblastomas of infancy exhibit a characteristic ganglioside pattern
2001 · Karen Kaucic, Nancy Etue, et al. · Cancer · 15
Advancing Global Health Equity in Oncology Clinical Trial Access
2024 · Bloomberg New Economy International Cancer Coalition, Tolulope Adewole, et al. · Cancer Discovery · 14
PDF
Modulation of human myelopoiesis by human gangliosides.
1994 · K Kaucic, A Grovas, et al. · PubMed · 14
Phase I Clinical Trial of the Anti-CD22 Immunotoxin CAT-8015 (HA22) for Pediatric Acute Lymphoblastic Leukemia (ALL).
2009 · Alan S. Wayne, Deepa Bhojwani, et al. · Blood · 9
Phase I Dose-Escalation Study of CAT-8015 (HA22), A CD22-Specific Targeted Immunotoxin, in Relapsed or Refractory Hairy Cell Leukemia.
2009 · Robert J Kreitman, Martin S. Tallman, et al. · Blood · 9
EBV-Related Lymphoproliferative Disease Complicating Therapy with Siplizumab, a Novel Anti-CD2 Mediated T- and NK-Cell Depleting Agent, in Patients with T-Cell Malignancies.
2007 · Deirdre O’Mahony, John C. Morris, et al. · Blood · 8
Supplementary Figure 1 from Advancing Global Health Equity in Oncology Clinical Trial Access
2026 · Tolulope Adewole, Bjorn Albrecht, et al.
Supplementary Table 1 from Advancing Global Health Equity in Oncology Clinical Trial Access
2024 · Tolulope Adewole, Bjorn Albrecht, et al.
Data from Advancing Global Health Equity in Oncology Clinical Trial Access
2024 · Tolulope Adewole, Bjorn Albrecht, et al.
Supplementary Figure 2 from Advancing Global Health Equity in Oncology Clinical Trial Access
2024 · Tolulope Adewole, Bjorn Albrecht, et al.
Supplementary Figure 1 from Advancing Global Health Equity in Oncology Clinical Trial Access
2024 · Tolulope Adewole, Bjorn Albrecht, et al.
PDF
Supplementary Tables S1-S3 from EBV-Related Lymphoproliferative Disease Complicating Therapy with the Anti-CD2 Monoclonal Antibody, Siplizumab, in Patients with T-Cell Malignancies
2023 · Deirdre O'Mahony, John C. Morris, et al.
Translation on this Article from EBV-Related Lymphoproliferative Disease Complicating Therapy with the Anti-CD2 Monoclonal Antibody, Siplizumab, in Patients with T-Cell Malignancies
2023 · Deirdre O'Mahony, John C. Morris, et al.
Data from EBV-Related Lymphoproliferative Disease Complicating Therapy with the Anti-CD2 Monoclonal Antibody, Siplizumab, in Patients with T-Cell Malignancies
2023 · Deirdre O'Mahony, John C. Morris, et al.
Data from EBV-Related Lymphoproliferative Disease Complicating Therapy with the Anti-CD2 Monoclonal Antibody, Siplizumab, in Patients with T-Cell Malignancies
2023 · Deirdre O'Mahony, John C. Morris, et al.
Translation on this Article from EBV-Related Lymphoproliferative Disease Complicating Therapy with the Anti-CD2 Monoclonal Antibody, Siplizumab, in Patients with T-Cell Malignancies
2023 · Deirdre O'Mahony, John C. Morris, et al.
Supplementary Tables S1-S3 from EBV-Related Lymphoproliferative Disease Complicating Therapy with the Anti-CD2 Monoclonal Antibody, Siplizumab, in Patients with T-Cell Malignancies
2023 · Deirdre O'Mahony, John C. Morris, et al.
PDF
Works count: 28
Citation count: 457
H-index: 11
I10-index: 11
Year
Topic
Type